LENZ Therapeutics, Inc. (NASDAQ:LENZ – Get Free Report) Director Ra Capital Management, L.P. purchased 998,009 shares of the business’s stock in a transaction on Thursday, March 21st. The stock was acquired at an average price of $15.03 per share, with a total value of $15,000,075.27. Following the purchase, the director now directly owns 3,319,339 shares in the company, valued at approximately $49,889,665.17. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.
LENZ Therapeutics Stock Up 30.3 %
Shares of LENZ stock opened at $21.81 on Thursday. LENZ Therapeutics, Inc. has a 52-week low of $14.07 and a 52-week high of $29.82. The firm has a market capitalization of $181.46 million, a price-to-earnings ratio of -1.40 and a beta of 0.20.
Analyst Upgrades and Downgrades
Separately, Piper Sandler began coverage on LENZ Therapeutics in a research note on Wednesday. They issued an “overweight” rating and a $28.00 price target for the company.
LENZ Therapeutics Company Profile
Graphite Bio Inc is a clinical-stage, next-generation gene editing company focused on therapies to treat or cure serious diseases. Graphite Bio Inc is based in SOUTH SAN FRANCISCO, Calif.
Featured Stories
- Five stocks we like better than LENZ Therapeutics
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Best Bear Market Funds: Top 3 Investment Options to Consider
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Is DraftKings A Good Bet Ahead of Q1 Earnings?
- What is a Special Dividend?
- Mid-Cap Stocks to Outperform the Market This Cycle
Receive News & Ratings for LENZ Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LENZ Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
